MetaCap

Agenus (AGEN) vs C4 Therapeutics (CCCC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agenus (AGEN) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 41.5% versus a gain of 1.6%. Over five years, AGEN leads with a -90.6% price change compared with -93.2% for CCCC. C4 Therapeutics is the larger company by market cap ($325.7 million vs $270.1 million), about 1.2 times the size, while Agenus is growing revenue faster (+10.4% vs +1.0%).

Agenus converts more of its revenue into profit, with a net margin of -2.7% versus -292.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGEN+41.47%CCCC+1.64%
+144%+50%-43%
Nov 21, 20251 yearNov 20, 2026
AGEN-91.28%CCCC-93.55%
+8%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGEN versus CCCC key metrics
MetricAGENCCCC
Share price$5.97$2.48
Market cap$270.12M$325.67M
1-day change-2.77%+1.64%
YTD return+90.13%+29.84%
1-year return+41.47%+1.64%
5-year return-90.58%-93.23%
P/E ratio (TTM)25.96—
EPS (TTM)$0.23$-0.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$114.20M$35.95M
Revenue growth (YoY)+10.37%+1.02%
Net income (latest FY)$-3.08M$-104.99M
Gross margin99.11%—
Operating margin-17.66%-320.53%
Net margin-2.70%-292.08%
52-week high$10.31$5.17
52-week low$2.71$1.69
Distance from 52-week high-42.10%-52.03%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.26%+404.03%
Average volume905.17K2.57M
Shares outstanding45.25M131.32M
Employees81104
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AGEN has outperformed CCCC by 39.8 percentage points over the past year.
  • Agenus is more profitable, keeping -2.7 cents of every revenue dollar as net income versus -292.1 cents for C4 Therapeutics.
  • Agenus grew revenue faster in its latest fiscal year (+10.37% vs +1.02%).

About Agenus

AGEN stock →

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

AGEN vs CCCC FAQ

Which is bigger, Agenus or C4 Therapeutics?

C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $270.12M for Agenus (AGEN).

Which stock has performed better over the past year, AGEN or CCCC?

AGEN returned +41.47% over the past 12 months, compared with +1.64% for CCCC (price return, excluding dividends). Past performance does not predict future results.

Are Agenus and C4 Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons